The Dow Misses a New Record as Merck, Pfizer, and J&J Lag

The Dow's three big pharma stocks led the list of declining components Friday. Find out what happened.

May 2, 2014 at 9:05PM

After climbing to potential new-record levels at the open, the Dow Jones Industrials (DJINDICES:^DJI) closed down almost 46 points on Friday, with trouble in Ukraine heating up and prompting an emergency meeting of the U.N. Security Council in response to violence in Black Sea port city Odessa. Even with news that the U.S. economy produced 288,000 new nonfarm jobs in April, the Dow couldn't overcome negative sentiment and fear of future trouble. Moreover, the Dow's full contingent of pharmaceutical stocks led the average downward, as Pfizer (NYSE:PFE), Merck (NYSE:MRK), and Johnson & Johnson (NYSE:JNJ) were the worst performers in the Dow Jones Industrials today.


A combination of factors helped hold the Dow's pharma stocks down Friday. For Pfizer, which fell 1.3%, the most likely culprit was news that the company's second attempt to buy out AstraZeneca had, once again, failed to gain acceptance, as the British drugmaker said that Pfizer's upped bid was still insufficient. With Pfizer offering about $106 billion for the company, investors have to be concerned that any further concessions to raise the price will start to erode the potential cost savings, and other advantages from a combination. In many ways, AstraZeneca is in the strongest negotiating position, as its domicile gives Pfizer a chance to take advantage of favorable foreign tax treatment, creating a huge opportunity for long-term savings. Shareholders might well have to accept paying even more in order to get the longer-term benefits of a merger deal.


Source: Steven Depolo, Flickr.

Meanwhile, Merck fell 2.4% after suffering a minor defeat on the clinical front, as a drug that Merck and a partner were hoping would become a viable treatment for ovarian cancer got a negative recommendation from the monitoring board overseeing the phase 3 trial. The results were somewhat shocking given positive results in other arenas, even for the same drug. But while it was a huge deal for the smaller partner company, the impact of stopping the trial isn't significant for Merck. News after the bell that an FDA panel voted against allowing Merck to sell its asthma treatment Singulair as an over-the-counter allergy medication could also hurt the drugmaker, although many saw the last-ditch effort to try to renew the now off-patent medication's ability to generate profits for Merck as unlikely to succeed.

Johnson & Johnson dropped 1.2%, seemingly in concert with its peers. Johnson & Johnson only gets about 40% of its revenue from pharmaceuticals, although that proportion has increased lately as the company emphasizes drug development over other segments like medical devices and over-the-counter products. Unlike Merck and Pfizer, Johnson & Johnson hasn't suffered from falling sales in recent years, as its diversified health-care exposure and different timeline of patent expirations has sheltered it from the full brunt of the patent cliff that Merck and Pfizer faced. Still, with Johnson & Johnson increasingly relying on pharmaceuticals as its main growth prospect, investors are right to link J&J's fortunes with those of Pfizer and Merck.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers